webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

DM3

  CAS No.: 796073-54-6   Cat No.: BADC-00339   Purity: ≥95% 4.5  

DM3 acts as an effective ADC cytotoxin payload disrupting DNA replication in tumor cells. Incorporated in antibody-drug conjugates, it boosts selective cancer cell killing with enhanced therapeutic performance.

DM3

Structure of 796073-54-6

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C37H52ClN3O10S
Molecular Weight
766.34
Target
Microtubule/Tubulin
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
5 mg $729 In stock
25 mg $1573 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
N2'-deacetyl-N2'-(4-mercapto-1-oxopentyl)- maytansine;
IUPAC Name
[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl(4-sulfanylpentanoyl)amino]propanoate
Canonical SMILES
CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCC(C)S)C)C)OC)(NC(=O)O2)O
InChI
InChI=1S/C37H52ClN3O10S/c1-20-11-10-12-28(48-9)37(46)19-27(49-35(45)39-37)22(3)33-36(5,51-33)29(50-34(44)23(4)40(6)30(42)14-13-21(2)52)18-31(43)41(7)25-16-24(15-20)17-26(47-8)32(25)38/h10-12,16-17,21-23,27-29,33,46,52H,13-15,18-19H2,1-9H3,(H,39,45)/b12-10+,20-11+/t21?,22-,23+,27+,28-,29+,33+,36+,37+/m1/s1
InChIKey
LJFFDOBFKICLHN-IXWHRVGISA-N
Appearance
Soild powder
Shipping
Room temperature
In Vitro
DM3 altered the expression of competence-induction pathways by upregulating CelA, CelB, and CglA while downregulating Ccs16, ComF, and Ccs4 proteins. Capsular polysaccharide subunits were downregulated in DM3-treated cells, however, it was upregulated in PEN- and DM3PEN-treated groups. Additionally, DM3 altered the amino acids biosynthesis pathways, particularly targeting ribosomal rRNA subunits. Downregulation of cationic AMPs resistance pathway suggests that DM3 treatment could autoenhance pneumococci susceptibility to DM3. Gene enrichment analysis showed that unlike PEN and DM3PEN, DM3 treatment exerted no effect on DNA-binding RNA polymerase activity but observed downregulation of RpoD and RNA polymerase sigma factor.

DM3 is a potent semi-synthetic derivative of Maytansine and a widely utilized ADC cytotoxin in the development of antibody-drug conjugates. As an ADC payload, DM3 disrupts microtubule polymerization by binding to tubulin, leading to mitotic arrest and apoptosis in rapidly dividing tumor cells. Its structural modifications compared to native Maytansine enhance conjugation efficiency and stability, making DM3 a versatile option for targeted cancer therapy applications.

Within antibody-drug conjugates, DM3 is typically linked to monoclonal antibodies using cleavable or non-cleavable linker strategies, ensuring selective payload release inside tumor cells. The ADC remains stable in systemic circulation, reducing off-target toxicity, while intracellular enzymatic processing liberates DM3 to exert its cytotoxic effects. This mechanism provides high tumor specificity, potent antitumor activity at low drug-to-antibody ratios (DARs), and improved therapeutic index, which are essential for precision oncology applications.

Applications of DM3 include its use in preclinical and clinical ADC candidates targeting hematologic malignancies and solid tumors, such as breast cancer, ovarian cancer, and lymphoma. Its chemical compatibility with diverse linker technologies allows researchers to optimize conjugation efficiency, stability, and intracellular payload release. DM3’s potent cytotoxicity and reliable pharmacokinetics make it a valuable ADC payload for developing next-generation antibody-drug conjugates with enhanced tumor selectivity and antitumor efficacy.

1. Lung function in divers
E Prokop, R Klos, M Konarski, K Korzeniewski, Aneta Nitsch-Osuch Adv Exp Med Biol . 2013;788:221-7. doi: 10.1007/978-94-007-6627-3_32.
Correct lung function is indispensible to perform work underwater. Thus, spirometric tests of lung function remain an important element in the process of selecting candidates for professional diving. Studies conducted in the population of divers identified the phenomenon called 'large lungs', which is often associated with spirometric indices characteristic of obstructive impairment of lung function. This study investigated selected parameters of lung function in the population of divers and candidates for professional divers. Fifty two male subjects were examined as part of the selection process. Basic spirometric tests: forced expiratory volume in 1 s (FEV1; dm(3)), forced vital capacity (FVC; dm(3)), forced expiratory flow in the range 25-75 % of FVC (FEF25-75; dm(3) s(-1)), and FEV1/FVC (%) were compared with compared with the predicted reference values estimated by the European Coal and Steel Community. The results demonstrate differences in FVC and FEF25-75 in divers, which may correspond to functional hyperinflation. The effects of 'large lungs' observed in divers, if persisting for an extended period of time, may lead to lung ventilation impairment of the obstructive type.
2. Electrodeposition of indium from non-aqueous electrolytes
Clio Deferm, Jan Fransaer, Koen Binnemans, Wouter Monnens, Jeroen Sniekers Chem Commun (Camb) . 2019 Apr 18;55(33):4789-4792. doi: 10.1039/c8cc10254f.
The electrochemical behaviour and deposition of indium in electrolytes composed of 0.4 mol dm-3 In(Tf2N)3 and 0.4 mol dm-3 InCl3 in the solvents 1,2-dimethoxyethane and poly(ethylene glycol) (average molecular mass of 0.400 kg mol-1, PEG400) was investigated. Indium(i) was identified as the intermediate species that disproportionated to indium(iii) and indium(0) nanoparticles. The presence of nanoparticles was verified by TEM analysis. SEM analysis showed that deposits obtained at room temperature from 1,2-dimethoxyethane were rough, while spherical structures were formed in PEG400 at 160 °C.
3. Bean and chia development in accordance with fertilization management
Tiago Roque Benetoli da Silva, Debora Fernandes Del Moura Soares, Gessica Daiane da Silva, Rhaizza Lana Pereira Ducheski, Jaqueline Calzavara Bordin-Rodrigues, Juliana Stracieri Heliyon . 2021 Jun 12;7(6):e07316. doi: 10.1016/j.heliyon.2021.e07316.
Chia seed is expanding on the market due to its characteristics, but there are few studies on its response to residual fertilization of other crops. The objective was to evaluate the vegetative and productive parameters of common bean as a function of the base fertilization increment and to verify the influence of the residue of this fertilization on the development of chia. The experiment was carried out in two stages, Maringá State University, Umuarama Regional Campus, in a randomized block design with 4 replications. The treatments for the first stage were: T1 - doses recommended for beans and T2, T3, T4 and T5, were recommended doses for beans with increments for each treatment. The evaluated variables were: shoot dry matter, number of pods per plant, grains per plant, grains per pod, 1000 grains weight and yield. In the second stage, the experiment was installed in the same place of the previous cultivation. The treatments were: residual bean fertilization, T6 - plus the treatment with the recommendation for chia. The evaluated variables were: macro and micronutrient leaf contents, shoot dry matter, final plant population, 1.000 grains weight, oil content and yield. For beans and chia, soil samples were collected after harvest to evaluate chemical attributes. In common bean, the results were not significant in the evaluated parameters. In soil, the residual effect of beans was significant for P and K, with 27.2 mg dm-3and 167.70 mg dm-3, in treatment T5 and chia was 23.1 mg dm-3and 89.7 mg dm-3, for treatment T6, respectively. In chia, yield, oil content and P for leaf macro and micronutrient leaf contents were significant. Thus, the vegetative and productive parameters of the common bean were not influenced by the increase in fertilization. The residual effect was higher for P and K, for beans and chia. For chia, influences by residual effect were observed.

What is DM3?

DM3 is a synthetic cytotoxic molecule derived from the maytansinoid family, utilized as a payload in ADCs. It inhibits microtubule assembly, disrupting mitosis and inducing apoptosis, suitable for targeted antibody conjugation.

2/11/2020

We are interested in how DM3 is applied in ADCs.

DM3 is linked to monoclonal antibodies to achieve selective cytotoxicity toward antigen-expressing cells. This targeted delivery minimizes off-target toxicity and enhances ADC therapeutic efficacy.

27/9/2019

Could you kindly inform us which linkers are effective with DM3?

DM3 can be conjugated using cleavable linkers for intracellular release and non-cleavable linkers for improved circulation stability. The choice of linker affects payload release kinetics and pharmacodynamic profile.

1/1/2019

May I ask what laboratory safety measures are recommended for DM3?

Handling DM3 requires PPE, proper containment, and adherence to institutional and regulatory safety guidelines due to its potent cytotoxicity. Proper waste disposal and safe handling during conjugation are essential.

12/8/2022

Dear BOC Sciences, what research benefits do DM3 ADCs provide?

DM3 ADCs deliver microtubule-targeting cytotoxicity selectively to target cells, enabling precise preclinical studies on antibody specificity, pharmacokinetics, and payload efficacy, supporting the development of safer oncology therapies.

2/7/2019

— Dr. Richard Evans, Senior Scientist (USA)

DM3 showed exceptional purity and stability. Shipment was timely and documentation thorough.

1/1/2019

— Prof. Emily Johnson, Chemical Biology Researcher (Canada)

We relied on BOC Sciences for DM3, and the compound delivered reliable cytotoxicity profiles in our assays. Their responsive support team made the process seamless.

2/7/2019

— Dr. Stefan Weber, Medicinal Chemist (Germany)

Technical support answered all questions and provided full QC reports for DM3.

12/8/2022

— Dr. David Wilson, Biotech Research Scientist (Canada)

The DM3 supplied by BOC Sciences was easy to handle and performed consistently during cytotoxicity assays. Their technical support also provided helpful insights on formulation.

2/11/2020

— Dr. Thomas Wright, Lead Scientist (USA)

High-purity DM3 compound and responsive service. Met all project needs.

— Prof. Anna Müller, Medicinal Chemistry Professor (Germany)

BOC Sciences supplied DM3 with excellent documentation, including HPLC and NMR profiles. This transparency helped us accelerate approval from our internal quality control team.

27/9/2019

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Cryptophycin 1 | Mal-PEG2-Val-Cit-PABA | N-(2-(2-Chlorophenoxy)ethyl)-4-Formylbenzamide | PTAD-PEG4-amine | APN-PEG4-tetrazine | 1-{[4-({4-[(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy]-4-oxobutyl}disulfanyl)butanoyl]oxy}-2,5-dioxopyrrolidine-3-sulfonic acid | Sibiromycin | Muscarinic toxin 2 | Fmoc-N-amido-PEG3-propionic acid | Chlorotoxin | DM3
Send Inquiry
Verification code
Inquiry Basket